Targeted clinical trials, wherein compounds are tested on patients with specific genetic traits, might lower development costs and subsequent prices for promising immunotherapies. Drugmakers are also experimenting with combinations of existing treatments that might cost less than single compounds. The FDA has become more flexible, speeding the approval process for drugs designated as breakthroughs and giving others priority review.
New approaches might lower drug prices
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|